Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 446 views

    FAMOTIDINE

    Uploaded by

    Cay Sevilla
    Drug Study

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOC, PDF, TXT or read online from Scribd

    FAMOTIDINE

    Uploaded by

    Cay Sevilla
    446 views3 pages
    Drug Study

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOC, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Drug Study

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    446 views3 pages

    FAMOTIDINE

    Uploaded by

    Cay Sevilla
    Drug Study

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    of 3

    FAMOTIDINE

    (fa-moe'ti-deen)
    Pepcid, Pepcid AC
    Classifications: gastrointestinal agent; antisecretory agent (h2-receptor antagonist)
    Prototype: Cimetidine
    Pregnancy Category: B

    Availability
    10 mg, 20 mg, 40 mg tablets; 40 mg/5 mL suspension; 10 mg/mL, 20 mg/50 mL injection

    Actions
    Thiazole derivative, structurally similar to histamine and pharmacologically similar to
    cimetidine. A potent competitive inhibitor of histamine at histamine (H2) receptor sites in
    gastric parietal cells. Inhibits basal, nocturnal, meal-stimulated, and pentagastrin-
    stimulated gastric secretion; also inhibits pepsin secretion. Is 20–160 times more potent
    than cimetidine and 3–20 times more potent than ranitidine. Does not affect gastric
    emptying or exocrine pancreatic function.

    Therapeutic Effects
    Reduces parietal cell output of hydrochloric acid; thus, detrimental effects of acid on
    gastric mucosa are diminished.

    Uses
    Short-term treatment of active duodenal ulcer. Maintenance therapy for duodenal ulcer
    patients on reduced dosage after healing of an active ulcer. Treatment of pathologic
    hypersecretory conditions (e.g., Zollinger-Ellison syndrome), benign gastric ulcer,
    gastroesophageal reflux disease (GERD), gastritis.

    Unlabeled Uses
    Stress ulcer prophylaxis.

    Contraindications
    Safe use during pregnancy (category B), by nursing mothers.
    Cautious Use
    Renal insufficiency.

    Route & Dosage

    Duodenal Ulcer
    Adult: PO 40 mg h.s. or 20 mg b.i.d. PO Maintenance Therapy 20 mg h.s. IV 20 mg
    q12h
    Child: PO/IV 0.5 mg/kg q8–12h (max: 40 mg/d)

    Pathological Hypersecretory Conditions


    Adult: PO 20–160 mg q6h

    GERD, Gastritis
    Adult: PO 10 mg b.i.d.
    Child: PO 1 mg/kg/d in 2 divided doses (max: 40 mg b.i.d.)

    Renal Impairment
    Clcr <50 mL/min: 50% of usual dose or usual dose q36–48h for all indications

    Administration
    Oral
     Give with liquid or food of patient's choice; an antacid may also be given if
    patient is also on antacid therapy.
     Store at 15°–30° C (59°–86° F). Protect from moisture and strong light; do not
    freeze.

    Intravenous
     Note: Verify correct IV concentration and rate of infusion/injection with
    physician before administration to infants or children.

    PREPARE: Direct: Dilute 20 mg (2 mL) famotidine IV solution (containing 10 mg/mL)


    with D5W, NS, or other compatible IV diluent (see manufacturer's directions) to a total
    volume of 5 or 10 mL.  IV Infusion: Dilute 2 mL famotidine IV with 100 mL
    compatible IV solution.  

    ADMINISTER: Direct: Give over not less than 2 min.  IV Infusion: Infuse over 15–30
    min.  

    INCOMPATIBILITIES Y-site: Amphotericin B cholesteryl complex, cefepime


     Store IV solution at 2°–8° C (36°–46° F); reconstituted IV solution is stable for 48
    h at room temperature 15°–30° C (59°–86° F).

    Adverse Effects ( 1%)


    CNS: Dizziness, headache, confusion, depression. GI: Constipation, diarrhea. Skin: Rash,
    acne, pruritus, dry skin, flushing. Hematologic: Thrombocytopenia. Urogenital: Increases
    in BUN and serum creatinine.

    Interactions
    Drug: No clinically significant interactions established.

    Pharmacokinetics
    Absorption: Incompletely absorbed from GI tract (40%–50% reaches systemic
    circulation). Onset: 1 h. Peak: 1–3 h PO; 0.5–3 h IV. Duration: 10–12 h. Metabolism:
    Metabolized in liver. Elimination: Excreted in urine. Half-Life: 2.5–4 h.

    NURSING IMPLICATIONS
    Assessment & Drug Effects

     Monitor for improvement in GI distress.


     Monitor for signs of GI bleeding.

    Patient & Family Education

     Be aware that pain relief may not be experienced for several days after starting
    therapy.
     Do not breast feed while taking this drug without consulting physician.

    Common adverse effects in italic, life-threatening effects underlined: generic names in


    bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

    Copyright © 2006 Pearson Education, Inc. All Rights Reserved

    You might also like